Evidence map›Paper›PMID 28051077›Full record

ArticleEuropean journal of human genetics : EJHG2017

FIG4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study.

Alma Osmanovic, Isolde Rangnau, Anne Kosfeld, Susanne Abdulla, Claas Janssen, Bernd Auber, Peter Raab, Matthias Preller, Susanne Petri, Ruthild G Weber

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Autophagy-lysosomal pathway in neurodegeneration.Molecular neurodegeneration advances · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. FIG4-associated disease manifesting as rapidly progressive amyotrophic lateral sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  16. Transient Receptor Potential Channels in the Healthy and Diseased Blood-Brain Barrier.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. The endolysosomal pathway and ALS/FTD.Trends in neurosciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alma OsmanovicDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Isolde RangnauDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Anne KosfeldDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Susanne AbdullaDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Claas JanssenDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Bernd AuberDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Peter RaabDepartment of Neuroradiology, Hannover Medical School, Hannover, Germany.
Matthias PrellerInstitute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.
Susanne PetriDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Ruthild G WeberDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DECentre for Structural Systems Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to identify the genetic cause of the devastating neurodegenerative disease amyotrophic lateral sclerosis (ALS) in a German family with two affected individuals, and to assess the prevalence of variants in the identified risk gene, FIG4, in a central European ALS cohort. Whole-exome sequencing (WES) and an overlapping data analysis strategy were performed in an ALS family with autosomal dominant inheritance and incomplete penetrance. Additionally, 200 central European ALS patients were analyzed using whole-exome or targeted sequencing. All patients were subjected to clinical, electrophysiological, and neuroradiological characterization to explore genotype-phenotype relationships. WES analysis of the ALS family identified the rare heterozygous frameshift variant FIG4:c.759delG, p.(F254Sfs*8) predicted to delete the catalytic domain and active center from the encoded phosphoinositide 5-phosphatase with a key role in endosomal vesicle trafficking. Additionally, novel or rare heterozygous FIG4 missense variants predicted to be deleterious were detected in five sporadic ALS patients revealing an overall FIG4 variant frequency of 3% in our cohort. Four of six variants identified were previously associated with ALS or the motor and sensory neuropathy Charcot-Marie-Tooth disease type 4J (CMT4J), whereas two variants were novel. In FIG4 variant carriers, disease duration was longer and upper motor neuron predominance was significantly more frequent compared with ALS patients without FIG4 variants. Our study provides evidence for FIG4 as an ALS risk gene in a central European cohort, adds new variants to the mutational spectrum, links ALS to CMT4J on a genetic level, and describes a distinctive ALS phenotype for FIG4 variant carriers.

Indexed as

ExomeFrameshift MutationMutation, MissenseAdultAgedAged, 80 and overAmyotrophic Lateral SclerosisCatalytic DomainEuropeFemaleFlavoproteinsGene FrequencyGenotypeHeterozygoteHumansMaleFIG4 protein, humanFlavoproteinsPhosphoric Monoester Hydrolases

Identifiers

PMID28051077
PMCPMC5315518
OpenAlexW2569020162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.